Breaking: The FDA has officially notified that it is reinstating the NDI status for Shangke Bio’s NMN raw material.
Classification: Company News
Publication:2025-12-09 09:41
On December 2, 2025, the U.S. Food and Drug Administration (FDA) formally responded to Shangke Bio’s notifications (NDINs 1240 and 1247) regarding the novel dietary ingredient β‑nicotinamide mononucleotide (NMN), confirming that, since NMN was not excluded as a novel dietary ingredient (NDI), the FDA has reinstated Shangke Bio’s NMN as a novel dietary ingredient and will publicly post the relevant information on the website www.regulations.gov under NDINs 1240 and 1247. To date, Shangke Bio remains the only company worldwide to have obtained NDI status for NMN raw material.
Shangke Bio’s Path to NMN NDI Approval
“New Dietary Ingredient” refers to a substance that meets the definition of a dietary ingredient but had not been marketed or used in the United States as a dietary supplement prior to October 15, 1994. Under Section 413(a)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 350b(a)(2)), any manufacturer or distributor intending to market a dietary supplement containing an NDI in the United States must submit an “NDI Notification” to the FDA before the product enters interstate commerce. An NDI Notification is a premarket submission; its filing does not constitute FDA approval, but rather enables the FDA to review whether the submitted information is sufficient and to determine whether the product can reasonably be considered safe under its intended conditions of use. If the information is insufficient or raises concerns, the FDA may request additional data; otherwise, placing the product on the market could expose the entity to legal risks.
On December 27, 2021, Shangke Biotechnology submitted New Dietary Ingredient Notification (NDIN) No. 1240, seeking approval to market NMN as a new dietary ingredient in the U.S. market. On February 24, 2022, the FDA responded to this notification, stating that, based on the available historical use data and other evidence, it could not establish the safety of NMN and therefore could not accept this ingredient for use in dietary supplements as a new dietary ingredient.
On March 21, 2022, Shangke Biotechnology once again submitted New Dietary Ingredient Notification (NDIN) No. 1247 to the FDA, seeking approval to list NMN as a new dietary ingredient. On May 16, 2022, the FDA issued an acknowledgment letter confirming receipt of the notification and published it on the Regulations.gov website on June 21, 2022, thereby permitting the legal sale of this ingredient in the U.S. market. However, on November 4, 2022, the FDA sent a supplementary response to Shangke Biotechnology, stating that NMN has been investigated as a new drug and thus falls under the pharmaceutical exclusion provision, precluding its use as a new dietary ingredient.
On March 7, 2023, the Natural Products Association (NPA), in collaboration with the Alliance for Natural Health (ANH), submitted a citizen petition to the FDA, requesting that the agency determine that NMN should not be excluded from the definition of a new dietary ingredient, or commit to exercising enforcement discretion when NMN is marketed as a dietary supplement. On September 29, 2025, the NPA announced that the FDA had formally responded to the citizen petition, confirming that NMN may be marketed as a new dietary ingredient.
On December 2, 2025, the FDA officially confirmed the reinstatement of Shangke Bio’s NMN as a new dietary ingredient. The resumption of Shangke Bio’s NMN NDI designation not only underscores the company’s unwavering commitment to global regulatory compliance but also reflects the FDA’s recognition of the product’s safety and quality. This represents significant positive news for the global NMN industry, making it increasingly likely that NMN will be formally approved as a dietary supplement ingredient in markets worldwide and paving the way for the sector’s continued, long-term standardization and growth.
Leave a Message Online
Shanghai Public Security Bureau Internet Information Service Security Filing No. 31011502015262